Cetrelimab

NORSE: erdafitinib + cetrelimab in mUC with FGFR alterations

Erdafitinib +/- cetrelimab in mUC patients with FGFR alterations

NORSE: erdafitinib and cetrelimab in urothelial carcinoma

Promising early results for cetrelimab plus erdafitinib reported for advanced UC | Thomas Powles

Medicine Matters oncology

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urot...

SunRISe-4 study

European Association of Urology

SESAUA 2024: TAR-210, 200 for NMIBC

GU Oncology Now

Will I feel like a guinea pig? Ask a Scientist about Clinical Trials

Cancer Research Institute

5 Immunotherapy for Cancer Treatment

Virginia Cancer Specialists

#ESMO21 Highlights on erdafitinib in adv. urothelial cancer with FGFRa alterations: The NORSE study

European Society for Medical Oncology (ESMO)

SunRISe-3: TAR-200 + CET or TAR-200 vs BCG in BCG-naive HR NMIBC

What to do in 2nd Line for bladder cancer? | Dr. Rana McKay | Oncology Brothers #oncology #cancer

OncBrothers: Practice-Changing Cancer Discussions

New Standard of Care treatment for Bladder Cancer | Dr. Rana McKay | Oncology Brothers #oncology

OncBrothers: Practice-Changing Cancer Discussions

GU Summary for ESMO 2023 | Dr. Rana McKay | Oncology Brothers #oncology

OncBrothers: Practice-Changing Cancer Discussions

ESMO 2023 GU Cancer Highlights – SunRISE-1, EV-302, PSMAfore | Oncology Brothers

OncBrothers: Practice-Changing Cancer Discussions

FGFR3 Inhibitors for Upper Tract Urothelial Cancer

Grand Rounds in Urology

Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metasta...

Ciclo "Carcinoma Urotelial de Vejiga" - Episodio IV

AAOC Comunicación

Erdafitinib demonstrates efficacy in intermediate-risk NMIBC with FGFR alterations

Dr. Petrylak Explains Prostate Cancer Clinical Trial Difficulties